Navigation Links
Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
Date:10/30/2008

SAN DIEGO, Oct. 30 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company, announced that the U.S. Patent and Trademark Office (USPTO) has issued two separate patents covering the technology for PROMETHEUS(R) Thiopurine Metabolites, a diagnostic test that enables physicians to optimize ongoing dosing of thiopurines to reach and maintain desired therapeutic levels. The USPTO has approved the issuance of the claims in U.S. Patent Nos. 7,425,546 and 7,429,570, both entitled, "Methods of optimizing drug therapeutic efficacy for treatment of immune- mediated gastrointestinal disorders."

"We are pleased that the USPTO has acknowledged the validity of these patents and approved their issuance," said William Franzblau, Vice President of Legal Affairs for Prometheus. "This is another example of our ongoing commitment to growing our substantial intellectual property portfolio, which we believe is a key competitive advantage. In addition, we will continue to protect and vigorously enforce our proprietary rights, if necessary."

PROMETHEUS(R) Thiopurine Metabolites helps keep patients' drug metabolite levels within an optimal therapeutic range, thereby increasing the probability of a positive response and potentially reducing the need for other medications. Thiopurine metabolites testing helps identify some of the reasons for treatment failure and monitor for potential toxicity before it occurs.

Combined, Prometheus' thiopurine management diagnostic tests - PROMETHEUS(R) TPMT Genetics and PROMETHEUS(R) TPMT Enzyme for individualizing dosing before therapy, and PROMETHEUS(R) Thiopurine Metabolites for optimizing dosing during therapy - provide information that helps physicians better manage therapeutic treatment, achieve better clinical outcomes and lower the potential for toxicity.

About Thiopurines

Thiopurines are a class of drugs that include azathioprine and mercaptopurine. These drugs are indicated as an adjunct for the prevention of rejection in renal homotransplantations, as well as for the management of active rheumatoid arthritis to reduce signs and symptoms. Although not indicated for inflammatory bowel disease, thiopurines are sometimes prescribed by physicians for such use. Their effectiveness and side effects can vary due to each person's ability to process or metabolize thiopurines. Most people have no problem metabolizing thiopurines, however, less than one percent of patients have almost no ability to metabolize these drugs. Failure to metabolize thiopurines can result in myelosuppression and hepatotoxicity, which can lead to death.

About Prometheus

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostics company committed to developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. Prometheus is currently focused on the detection, diagnosis and treatment of gastrointestinal diseases and disorders in the United States. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary, high-value diagnostic testing services. By integrating pharmaceutical products and diagnostic testing services, Prometheus believes it can address the full continuum of care, thereby providing physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Prometheus Licenses COLAL-PRED(R) From Alizyme
2. Medpace Strengthens Presence in Central Europe
3. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
4. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
5. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
6. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
7. Anavex strengthens Board of Directors
8. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
9. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
10. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017   KCNQ2 Cure Alliance ... evaluations company, today announced that they have completed ... genetic mutation implicated in KCNQ2 epileptic encephalopathy. They ... a second case involving an additional KCNQ2 genetic ... Alliance and Pairnomix entered into a collaboration to ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to make clinical trial sites and study participants truly unified. TrialKit, a native ... (FDA 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or quartz parts can be ... capabilities to properly execute your job can take many hours of emails, phone calls ... portal designed to showcase the company’s capabilities and core custom categories, and enables you ...
(Date:7/18/2017)... ... , ... G-CON today announced that it has received Notices ... Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile Clean Room. The U.S. ... of G-CON’s R&D investments and validate the G-CON platform as a novel way ...
Breaking Biology Technology:
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Biology News(10 mins):